bullish
I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry
372 Views08 Jul 2020 15:10
I-Mab was listed in the US on Jan 17th and returned 96% since listing. I-Mab has a highly differentiated two segments of products, including...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Everest Medicines (1952.HK) - The Commercialization Prospect Has Reshaped25 May 2021
- I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ10129 Mar 2021
- I-Mab Placement - Heading in the Right Direction08 Feb 2021
- I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation17 Jan 2020
- I-Mab (天境生物) IPO: Everest Deal a Valuation Booster06 Jan 2020
x